Salarius Pharmaceuticals to Report Second Quarter 2020 Financial Results
August 05 2020 - 9:30AM
Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a
clinical-stage biotechnology company targeting cancers caused by
dysregulated gene expression, announced that the Company will host
a conference call and live audio webcast on Wednesday, August 12,
2020, at 4:30 p.m. ET, to discuss its corporate and financial
results for the second quarter 2020.
Conference Call Information:
Interested participants and investors may access the conference
call by dialing either:
- (833) 423-0481 (U.S.)
- (918) 922-2375 (international)
- Conference ID: 9367616
An audio webcast will be accessible via the Investors Events
& Presentations section of the Company’s website,
http://investors.salariuspharma.com/. An archive of the webcast
will remain available for 90 days beginning at approximately 5:30
p.m. ET, on Wednesday, August 12, 2020.
About Salarius Pharmaceuticals Salarius
Pharmaceuticals, Inc. is a clinical-stage oncology company
targeting cancers caused by dysregulated gene expression and is
developing treatments for patients that need them the most.
Epigenetics refers to the regulatory system that affects gene
expression. Salarius’ lead candidate, seclidemstat, is currently in
a Phase 1/2 clinical trial for relapsed/refractory
Ewing sarcoma, for which it has received Fast Track
Designation, Orphan Drug Designation and Rare Pediatric Disease
Designation from the U.S. Food and Drug Administration.
Salarius is also developing seclidemstat for several cancers with
high unmet medical need, with a second Phase 1/2 clinical study in
advanced solid tumors, including prostate, breast, and ovarian
cancers. Salarius receives financial support from the National
Pediatric Cancer Foundation to advance the Ewing sarcoma
clinical program and is also the recipient of an $18.7
million Product Development Award from the Cancer
Prevention and Research Institute of Texas (CPRIT). For more
information, please visit salariuspharma.com.
Contact
Investor RelationsTiberend Strategic Advisors,
Inc.Maureen McEnroe, CFA/Miriam Miller(212) 375-2664 /
2694mmcenroe@tiberend.commmiller@tiberend.com
Media Relations Tiberend Strategic Advisors,
Inc. Johanna Bennett (212) 375-2686 jbennett@tiberend.com
Salarius Pharmaceuticals (NASDAQ:SLRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Salarius Pharmaceuticals (NASDAQ:SLRX)
Historical Stock Chart
From Apr 2023 to Apr 2024